UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
March 27, 2014
Date of Report (Date of earliest event reported)
Auspex Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-36292 | | 95-4862842 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
3366 N. Torrey Pines Court, Suite 225 San Diego, CA | | 92037 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 558-2400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 27, 2014, the Compensation Committee of the Board of Directors of Auspex Pharmaceuticals, Inc. (the “Company”) approved discretionary cash bonuses for certain of the Company’s named executive officers and the Company’s principal financial officer, payable in the amounts shown below:
| | | | |
Name / Title | | Bonus Amount | |
| |
John Schmid, Chief Financial Officer | | $ | 82,500 | |
| |
Andreas Sommer, Ph.D., Chief Scientific Officer | | $ | 60,000 | |
| |
David Stamler, M.D., Chief Medical Officer | | $ | 82,500 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | Auspex Pharmaceuticals, Inc. |
| | |
| Dated: April 1, 2014 | | | | |
| | | |
| | | | By: | | /s/ Pratik Shah |
| | | | | | Pratik Shah, Ph.D. |
| | | | | | President and Chief Executive Officer |
